Home-based neuro-cardiac rehabilitation in congenital heart disease: the QUALINEURO-REHAB trial study protocol
27 affiliations
- 1Cardiac Neurodevelopmental Center - CNC Necker, National Reference Center for Complex Congenital Heart Diseases M3C, APHP, Université Paris Cité, Hôpital Necker-Enfants Malades, Paris, France
- 2French National Institute of Health and Medical Research, PhyMedExp, Cardiac Neurodevelopmental Research Group, Inserm U1046, Montpellier, France
- 3Unit of Pediatric and Congenital Cardiology, Montpellier University Hospital, Montpellier, France
- 4Department of Pediatric and Congenital Cardiology, National Reference Centre for Complex Congenital Heart Disease, Bordeaux, France
- 5Department of Congenital Heart Defects and Pediatric Cardiology, TUM University Hospital, Deutsches Herzzentrum München, Munich, Germany
- 6INSERM U1045, University of Bordeaux, IHU Liryc Institut des Maladies du Rythme Cardiaque, Pessac, France
- 7Epidemiology and Clinical Research Department, Montpellier University Hospital, Montpellier, France
- 8Public Health Department, Bordeaux University Hospital, Bordeaux, France
- 9Public Health Department, Medical Information Unit, CHU Bordeaux, Bordeaux, France
- 10Bordeaux Population Health, INSERM U1219, Bordeaux, France
- 11USMR, CHU de Bordeaux, Bordeaux, France
- 12Pediatric cardiology, University Hospital Centre Bordeaux, Pessac, France
- 13Le Hillot Cardiac Rehabilitation Center, Bordeaux, France
- 14Division of Pediatric Cardiology, Department of Pediatrics, Cliniques universitaires Saint-Luc, Brussels, Belgium
- 15UCLouvain, Louvain-la-Neuve, Belgium
- 16Montpellier University Hospital, Montpellier, France
- 17Pediatric Cardiology, University Hospital of Montpellier, Montpellier, France
- 18U1046 PhyMedExp, National Institute of Health and Medical Research, Montpellier, France
- 19Patient Association Petit Coeur de Beurre, La Garenne Colombes, France
- 20Patient Association Petit Coeur de Beurre, Paris, France
- 21Department of Congenital Heart Defects and Pediatric Cardiology, Deutsches Herzzentrum München, Munich, Germany
- 22TUM University Hospital, Munich, Germany
- 23Clinical Research and Innovation Department, Bordeaux University Hospital, Bordeaux, France
- 24M3C Cardiologie Pediatrique, Hôpital Universitaire Necker-Enfants Malades, Paris, France
- 25University Hospital of Montpellier, Montpellier, France
- 26Department of Pediatric and Congenital Cardiology, George Washington University School of Medicine & Health Sciences, Heart & Lung Center — Children’s National Hospital, Washington, DC, USA
- 27University of Bordeaux, Talence, France
Abstract
Introduction Neurodevelopmental impairments and physical deconditioning are the most common long-term morbidities in congenital heart disease (CHD). Holistic interventions including combined neuro-cardiac training may improve physical and mental health in youth with CHD. Methods and analysis This is a European multicentre, two-arm randomised controlled study to test the efficacy of a home-based neuro-cardiac rehabilitation programme including physical activity and neuropsychological training versus the standard of care in children, adolescents and young adults with complex CHD. Patients aged 8–25 years who underwent infant surgical and/or catheter-based cardiac interventions will be randomly allocated to either an intervention group including a 12-week home-based cardiovascular rehabilitation and executive function training or to a control group. All participants will undergo a baseline assessment and a 12-month follow-up. The primary outcome is the difference in change in the Pediatric Quality of Life Inventory self-reported health-related quality of life score between baseline and final assessment for the intervention versus the control group. Secondary outcomes include standardised neuropsychological measures of executive function, social cognition and mental health. Cardiovascular secondary outcomes include cardiopulmonary fitness parameters such as maximum oxygen uptake, muscular strength and level of physical activity. Efficacy of the intervention will be evaluated by comparing within-subject group differences from baseline to 12-month follow-up, using an intention-to-treat analysis. Ethics and dissemination The trial protocol was first approved by the sponsor’s drawn National Ethics Committee (CPP Paris-III, number 2023-A00038-37) and registered on Clinicaltrial.gov (number NCT05670132 ). It was also approved by Ethics Committees in Germany (Technische Universitat Munchen, number 2023-276-S-KH) and Belgium (UCLouvain, number B4032025000116). Trial registration number NCT05670132 .
Related
- ITACARE-P cardiorehab registry: real-world data on quality and outcomes in heart failure and ischaemic heart disease - a prospective observational study protocol of the Italian early post-acute cardiac rehabilitation network.
- Risk factors for acute gastrointestinal injury after cardiac surgery in underweight children with congenital heart disease: a single-center retrospective study
- Symbolic transfer entropy reveals enhanced cardiac autonomic influence on cortical activity in infants with congenital heart disease
- Exercise‐based cardiac rehabilitation for coronary heart disease
- MUSIC‐PD: A Delphi‐Derived, Culturally Adaptable Music Therapy Protocol for Parkinson's Disease Rehabilitation
BibTeX
@article{calderon2026homebased,
title = {{Home-based neuro-cardiac rehabilitation in congenital heart disease: the QUALINEURO-REHAB trial study protocol}},
author = {Johanna Calderon and Sylvie Martins and Alfred Hager and Lauriane Cornuault and Cecile Jore and Mathieu Andrianoely and Marie-Christine Picot and Florence Francis and Florence Saillour and Marion Kret and Anne Cécile Huby and Marion Audie and Pierre-Marie Duboue and Jelena Hubrechts and Gregoire De La Villeon and Marie Vincenti and Gaelle Marguin and Gwladys Desmure and Julia Hock and David Schmitz and Damien Bonnet and Stephane Moniotte and Sophie Guillaumont and Pascal Amedro},
journal = {BMJ Open},
year = {2026},
month = oct,
doi = {10.1136/bmjopen-2026-120953},
url = {https://hal.science/hal-05780114v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Home-based neuro-cardiac rehabilitation in congenital heart disease: the QUALINEURO-REHAB trial study protocol
AU - Johanna Calderon
AU - Sylvie Martins
AU - Alfred Hager
AU - Lauriane Cornuault
AU - Cecile Jore
AU - Mathieu Andrianoely
AU - Marie-Christine Picot
AU - Florence Francis
AU - Florence Saillour
AU - Marion Kret
AU - Anne Cécile Huby
AU - Marion Audie
AU - Pierre-Marie Duboue
AU - Jelena Hubrechts
AU - Gregoire De La Villeon
AU - Marie Vincenti
AU - Gaelle Marguin
AU - Gwladys Desmure
AU - Julia Hock
AU - David Schmitz
AU - Damien Bonnet
AU - Stephane Moniotte
AU - Sophie Guillaumont
AU - Pascal Amedro
PY - 2026
DA - 2026/10/05
JO - BMJ Open
DO - 10.1136/bmjopen-2026-120953
UR - https://hal.science/hal-05780114v1
AB - Introduction Neurodevelopmental impairments and physical deconditioning are the most common long-term morbidities in congenital heart disease (CHD). Holistic interventions including combined neuro-cardiac training may improve physical and mental health in youth with CHD. Methods and analysis This is a European multicentre, two-arm randomised controlled study to test the efficacy of a home-based neuro-cardiac rehabilitation programme including physical activity and neuropsychological training versus the standard of care in children, adolescents and young adults with complex CHD. Patients aged 8–25 years who underwent infant surgical and/or catheter-based cardiac interventions will be randomly allocated to either an intervention group including a 12-week home-based cardiovascular rehabilitation and executive function training or to a control group. All participants will undergo a baseline assessment and a 12-month follow-up. The primary outcome is the difference in change in the Pediatric Quality of Life Inventory self-reported health-related quality of life score between baseline and final assessment for the intervention versus the control group. Secondary outcomes include standardised neuropsychological measures of executive function, social cognition and mental health. Cardiovascular secondary outcomes include cardiopulmonary fitness parameters such as maximum oxygen uptake, muscular strength and level of physical activity. Efficacy of the intervention will be evaluated by comparing within-subject group differences from baseline to 12-month follow-up, using an intention-to-treat analysis. Ethics and dissemination The trial protocol was first approved by the sponsor’s drawn National Ethics Committee (CPP Paris-III, number 2023-A00038-37) and registered on Clinicaltrial.gov (number NCT05670132 ). It was also approved by Ethics Committees in Germany (Technische Universitat Munchen, number 2023-276-S-KH) and Belgium (UCLouvain, number B4032025000116). Trial registration number NCT05670132 .
SN - 2044-6055
ER -